SONOMA PHARMACEUTICALS (SNOA) Q2 FY2026 (Ended Sep 30, 2025) TL;DR
Financial Performance & Liquidity Crisis: Sonoma Pharmaceuticals reported robust top-line growth, with Q3 revenue climbing 57% year-over-year to \(5.604M, driving total six-month revenue to \)9.619M (up 38%). Operating leverage improved substantially in Q3, narrowing the operating loss to \((0.337M)\). However, the company consistently reports net losses; the six-month net loss was \((1.775M)\). Critically, management explicitly stated substantial doubt about the ability to continue as a going concern within one year, ci
...